ArticleThe World Allergy Organization journal2025
Comparison of three-bag and single-bag protocols in rapid drug desensitization with chemotherapeutic and biological agents.
Article in The World Allergy Organization journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rapid drug desensitization (RDD) for patients experiencing hypersensitivity reactions (HSRs) to chemotherapeutics and biological therapeutic agents allows for temporary tolerance to the implicated drug, since this procedure requires intensive labor and time, alternative single-bag RDD protocols have been developed. We aimed to share our experiences with single-bag and multi-bag RDD in patients with HSRs to chemotherapeutics and biological agents. Materials and methods: Patients who were administered a single or three-bag RDD with implicated chemotherapeutics and biological agents between January 2020-August 2024 were included. The severity of HSRs was classified according to the Brown classification. Prick and intradermal tests were performed with the implicated drugs. Results: A total of 153 patients (F:121, M:32, Mean age:56.7 ± 11.4) were included, 109 of whom had experienced HSRs to platinum, 37 to taxanes, and 7 to biological agents. The initial severity was mostly grade 2 (n:84,54.9%) or grade 3 (n:50,32.7%). Skin testings were positive in 70 of 139 patients tested. A total of 582 RDD procedures were performed to 76 patients with the single bag-12-step protocol and to 77 patients with the three-bag-12-step protocol. No statistically significant differences were found between the single-bag and three-bag groups regarding age, sex, atopy, presence of comorbidities, initial reaction severity, and skin test positivity. During the 582 RDD procedures, 44 breakthrough reactions (22 in each group) occurred. Ultimately, 581 out of 582 RDD procedures (99.8%) were successfully completed, except one patient with grade 2 reaction in the single-bag group. The desensitization procedures were completed in 273 ± 42 min for the single-bag group and in 367 ± 33 min for the three-bag group (p-value <0.001). Conclusions: Our study demonstrated that the single-bag protocol is as safe and effective as the three-bag protocol, while also providing a time-saving advantage. Thus, it is considered a viable alternative to multi-bag desensitization protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.